DK1235776T3 - Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorer - Google Patents
Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorerInfo
- Publication number
- DK1235776T3 DK1235776T3 DK00972945T DK00972945T DK1235776T3 DK 1235776 T3 DK1235776 T3 DK 1235776T3 DK 00972945 T DK00972945 T DK 00972945T DK 00972945 T DK00972945 T DK 00972945T DK 1235776 T3 DK1235776 T3 DK 1235776T3
- Authority
- DK
- Denmark
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor modulators
- ch2ch2oh
- och3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/16—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16582899P | 1999-11-16 | 1999-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1235776T3 true DK1235776T3 (da) | 2006-04-10 |
Family
ID=22600649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00972945T DK1235776T3 (da) | 1999-11-16 | 2000-11-01 | Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorer |
Country Status (30)
Country | Link |
---|---|
US (2) | US6576645B1 (he) |
EP (1) | EP1235776B1 (he) |
JP (1) | JP4202647B2 (he) |
KR (2) | KR100877487B1 (he) |
CN (2) | CN100441556C (he) |
AT (1) | ATE317378T1 (he) |
AU (1) | AU778296B2 (he) |
BG (1) | BG65853B1 (he) |
BR (1) | BRPI0014901B8 (he) |
CA (1) | CA2390116C (he) |
CZ (1) | CZ304738B6 (he) |
DE (1) | DE60025938T2 (he) |
DK (1) | DK1235776T3 (he) |
EE (1) | EE05126B1 (he) |
ES (1) | ES2253268T3 (he) |
HK (1) | HK1051850A1 (he) |
HR (1) | HRP20020223C1 (he) |
HU (1) | HU228512B1 (he) |
IL (2) | IL148198A0 (he) |
MX (1) | MXPA02002154A (he) |
NO (2) | NO328010B1 (he) |
NZ (1) | NZ518542A (he) |
PL (1) | PL201512B1 (he) |
PT (1) | PT1235776E (he) |
RU (1) | RU2247715C2 (he) |
SK (1) | SK287752B6 (he) |
TW (1) | TW593256B (he) |
UA (1) | UA76409C2 (he) |
WO (1) | WO2001036360A1 (he) |
ZA (1) | ZA200201433B (he) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
FI111710B (fi) | 2001-05-04 | 2003-09-15 | Hormos Medical Oy Ltd | Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
JP5013593B2 (ja) | 2003-07-28 | 2012-08-29 | スミスクライン ビーチャム コーポレーション | 化合物 |
US7196119B2 (en) | 2003-10-21 | 2007-03-27 | The Regents Of The University Of California | Development of new selective estrogen receptor modulators |
CA2578852A1 (en) * | 2004-09-03 | 2006-03-09 | Hormos Medical Corporation | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
AU2006339325A1 (en) * | 2005-11-09 | 2007-09-07 | Hormos Medical Ltd. | Formulations of fispemifene |
US20080255078A1 (en) * | 2005-11-22 | 2008-10-16 | Subba Reddy Katamreddy | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators |
EP1951217A4 (en) * | 2005-11-22 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
JP2009516746A (ja) * | 2005-11-22 | 2009-04-23 | スミスクライン ビーチャム コーポレーション | 化合物 |
WO2007062151A2 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Chemical compounds |
KR101505884B1 (ko) | 2006-05-22 | 2015-03-25 | 호르모스 메디칼 리미티드 | 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제 |
CN101636372B (zh) | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
US20080312239A1 (en) * | 2007-06-13 | 2008-12-18 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
CA2702710C (en) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Trans-clomiphene for metabolic syndrome |
WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
DK2526080T3 (da) | 2010-01-19 | 2014-04-28 | Cambrex Karlskoga Ab | Nye fremgangsmåder til fremstilling af benzophenonderivater |
EP2571923B1 (de) * | 2010-05-20 | 2014-12-17 | Basf Se | Derivate von tris(2-hydroxyphenyl)methan, deren herstellung und verwendung |
DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
KR101308258B1 (ko) * | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
CA2861939A1 (en) * | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
CN102532073A (zh) * | 2011-12-30 | 2012-07-04 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
ES2681023T3 (es) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Terapia de combinación para tratar el déficit de andrógenos |
SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
US20150321983A1 (en) | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
IN2013MU00646A (he) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
CN107074722A (zh) * | 2014-09-16 | 2017-08-18 | 盐野义制药株式会社 | 三苯基丁烯衍生物的制造方法 |
CA2971216A1 (en) | 2014-12-23 | 2016-06-30 | The Regents Of The University Of California | Methods for immunomodulation of cancer and infectious disease therapy |
CN108348605B (zh) | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
EP3835285A1 (en) | 2016-03-15 | 2021-06-16 | Shionogi & Co., Ltd | Method for producing phenoxyethanol derivative |
KR101819639B1 (ko) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
EP3459936B1 (en) * | 2016-06-27 | 2022-04-27 | Daegu-Gyeongbuk Medical Innovation Foundation | Novel aryl ethane derivative and pharmaceutical composition containing same as active ingredient |
KR102052133B1 (ko) * | 2017-08-10 | 2019-12-05 | 고려대학교 산학협력단 | 당 부가된 오스페미펜, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
WO2019103989A1 (en) * | 2017-11-22 | 2019-05-31 | Temple University-Of The Commonwealth System Of Higher Education | Novel functionalized n,n-dialkylamino phenyl ethers and their method of use |
US10696659B2 (en) * | 2018-11-21 | 2020-06-30 | Accutar Biotechnology Inc. | Compounds having estrogen receptor alpha degradation activity and uses thereof |
CA3161892A1 (en) | 2019-12-23 | 2021-07-01 | Jie Fan | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
US11413270B2 (en) | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
US11850246B2 (en) | 2020-08-04 | 2023-12-26 | Novmetapharma Co., Ltd. | Method for treatment of cytokine release syndrome |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (he) | 1962-09-13 | |||
GB2042519B (en) * | 1979-01-17 | 1983-03-23 | Biorex Laboratories Ltd | 1,1,2-triphenylethane and -ehylene derivatives |
US4656187A (en) | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
EP0260066B1 (en) * | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifen derivatives |
US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
CA2092996A1 (en) | 1990-10-01 | 1992-04-02 | David Yang | High affinity tamoxifen derivatives and uses thereof |
US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5196435A (en) | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5446203A (en) | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
DE4335876A1 (de) | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5604248A (en) | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5470883A (en) | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
US5441986A (en) | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5658931A (en) | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
EP0794771A1 (en) | 1994-11-29 | 1997-09-17 | Hoechst Marion Roussel, Inc. | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis |
US5821254A (en) | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
GB9509572D0 (en) * | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
GB9803521D0 (en) * | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
-
2000
- 2000-10-20 TW TW089122073A patent/TW593256B/zh not_active IP Right Cessation
- 2000-11-01 AU AU11503/01A patent/AU778296B2/en not_active Ceased
- 2000-11-01 HU HU0204029A patent/HU228512B1/hu not_active IP Right Cessation
- 2000-11-01 UA UA2002065002A patent/UA76409C2/uk unknown
- 2000-11-01 EP EP00972945A patent/EP1235776B1/en not_active Expired - Lifetime
- 2000-11-01 CN CNB200610084709XA patent/CN100441556C/zh not_active Expired - Lifetime
- 2000-11-01 EE EEP200200190A patent/EE05126B1/xx unknown
- 2000-11-01 JP JP2001538315A patent/JP4202647B2/ja not_active Expired - Lifetime
- 2000-11-01 CZ CZ2002-1623A patent/CZ304738B6/cs not_active IP Right Cessation
- 2000-11-01 BR BRPI0014901A patent/BRPI0014901B8/pt not_active IP Right Cessation
- 2000-11-01 CA CA002390116A patent/CA2390116C/en not_active Expired - Lifetime
- 2000-11-01 KR KR1020027006302A patent/KR100877487B1/ko active IP Right Grant
- 2000-11-01 DK DK00972945T patent/DK1235776T3/da active
- 2000-11-01 MX MXPA02002154A patent/MXPA02002154A/es active IP Right Grant
- 2000-11-01 AT AT00972945T patent/ATE317378T1/de active
- 2000-11-01 NZ NZ518542A patent/NZ518542A/xx not_active IP Right Cessation
- 2000-11-01 ES ES00972945T patent/ES2253268T3/es not_active Expired - Lifetime
- 2000-11-01 RU RU2002115871/04A patent/RU2247715C2/ru active
- 2000-11-01 CN CNB008156255A patent/CN1263720C/zh not_active Expired - Lifetime
- 2000-11-01 PT PT00972945T patent/PT1235776E/pt unknown
- 2000-11-01 WO PCT/FI2000/000946 patent/WO2001036360A1/en active IP Right Grant
- 2000-11-01 SK SK671-2002A patent/SK287752B6/sk not_active IP Right Cessation
- 2000-11-01 KR KR1020087000375A patent/KR20080015924A/ko not_active Application Discontinuation
- 2000-11-01 IL IL14819800A patent/IL148198A0/xx unknown
- 2000-11-01 PL PL355708A patent/PL201512B1/pl unknown
- 2000-11-01 DE DE60025938T patent/DE60025938T2/de not_active Expired - Lifetime
- 2000-11-15 US US09/712,252 patent/US6576645B1/en not_active Expired - Lifetime
-
2002
- 2002-02-14 BG BG106413A patent/BG65853B1/bg unknown
- 2002-02-17 IL IL148198A patent/IL148198A/he not_active IP Right Cessation
- 2002-02-20 ZA ZA200201433A patent/ZA200201433B/en unknown
- 2002-03-14 HR HR20020223 patent/HRP20020223C1/xx not_active IP Right Cessation
- 2002-05-15 NO NO20022317A patent/NO328010B1/no not_active IP Right Cessation
-
2003
- 2003-04-08 US US10/408,303 patent/US6875775B2/en not_active Expired - Lifetime
- 2003-06-10 HK HK03104083A patent/HK1051850A1/xx not_active IP Right Cessation
-
2009
- 2009-10-20 NO NO20093175A patent/NO332328B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1235776T3 (da) | Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorer | |
MY114679A (en) | Aroyl-piperidine derivatives | |
TR200401413T1 (tr) | Dibenzilamin bileşikleri ve bunların farmasötik kullanımları | |
DK1260512T3 (da) | Hidtil ukendte, cykliske amidderivater | |
ES2185338T3 (es) | Derivados de fumagilol y procedimientos para su fabricacion. | |
HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
HRP20030003B1 (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
TR200100698T2 (tr) | 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri | |
ES2191341T3 (es) | Derivados de la 2-fenoxianilina. | |
DK0404359T3 (da) | Dibenzothiazepin-derivater, der er nyttige som antispasmodiske midler | |
HUP0303361A2 (hu) | Helyettesített 1-amino-bután-3-ol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
RS50289B (sr) | Novi razgranati supstituisani amino derivati od 3-amino-1- fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
AR034313A1 (es) | Utilizacion de derivados de piridoindolona para la preparacion de medicamentos | |
NO20040113L (no) | Variolinderivater og deres anvendelse som antitumormidler | |
DE69828087D1 (de) | Aminderivate | |
NO955071L (no) | abeo-Ergolin-derivater som 5HT1A-ligander | |
CO4940434A1 (es) | Derivados terapeuticos de naftaleno | |
WO2001064671A3 (fr) | Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4 | |
SE9002445D0 (sv) | Nytt cyklobutanderivat och foerfarande foer framstaellning av detsamma | |
ES464875A1 (es) | Un procedimiento para la preparacion de nuevos compuestos tetraciclicos | |
TH34907A (th) | สารประกอบใหม่ |